XTRA:MRKPharmaceuticals
Assessing Merck KGaA (XTRA:MRK) Valuation Following Leadership Shift in Global R&D
If you have been following Merck KGaA (XTRA:MRK), the recent appointment of David Weinreich as Global Head of R&D and Chief Medical Officer for its Healthcare division is a change you will want to note. Weinreich arrives with a strong reputation for steering drug development and guiding large teams through periods of transformation. This appointment has the potential to reshape Merck KGaA's innovation pipeline. Given his track record in getting new therapies to market, investors are...